Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy

Author(s):
Johnson, K.C.; Aragaki, A.K.; Jackson, R.; Reiner, A.; Sandset, P.M.; Rosing, J.; Dahm, A.E.A.; Rosendaal, F.; Manson, J.E.; Martin, L.W.; Liu, S.M.; Kuller, L.H.; Cushman, M.; Rossouw, J.E.
Published
2016
Publication type
Article / Letter to editor
activated protein C resistancecoronary diseaseestrogenshemostaticsprogestinstissue factor pathway inhibitor activity
Date issued
2016-02-28
Language
English
Is part of
Arteriosclerosis, Thrombosis, and Vascular Biology (2016), Vol. 36, no. 2, p. 418-424
hdl
1887/113149
doi
10.1161/ATVBAHA.115.306905